-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The results of clinical trials for stroke prevention in patients with atrial fibrillation consistently show that taking warfarin or non-vitamin K antagonist oral anticoagulants (NOAC) can achieve clinical benefits.
Stroke prevention
Recently, the medsci.
medsci.
The cases in this study were consecutive patients with atrial fibrillation who developed ICH during NOAC treatment.
The study included 419 patients (mean age of 78.
It can be seen that some risk factors are related to the occurrence of ICH in patients taking NOAC to prevent stroke, but the HAS-BLED and CHA2DS2-VASc scores are not related to them .
Some risk factors are related to the occurrence of ICH in patients taking NOAC to prevent stroke, but HAS-BLED and CHA2DS2-VASc scores are not related to them
Original source:
Original source:Maurizio Paciaroni.